Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Proteros biostructures GmbH announced it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV triggering an undisclosed payment to Proteros.
Proteros has collaborated with Janssen for over a decade supporting numerous projects across all therapeutic areas. The objective of this oncology focused project was for Proteros to discover potent and selective small molecule inhibitor series against a novel protein target. Based on the establishment of a de novo X-ray crystallography system, HTS screening and biophysical assay technology of the novel target Proteros delivered multiple chemical series meeting stringent compound criteria.
Dr. Peter Reinemer, Chief Operating Officer for Proteros, stated: "We are very pleased to be Janssen's partner in one of their oncology discovery programs and that we have been able to deliver new compound classes for a challenging novel drug target."
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Successfully Treating Genetically Determined Autoimmune Enteritis

How do genes get new jobs? - Wasp venom offers new insights
Anti-Cancer Project Originating from LDC Reaches Next Milestone - Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG
Convergence Pharmaceuticals Announces Start of Phase II Study for CNV1014802 for Trigeminal Neuralgia
Biotech Crops Poised for Second Wave of Growth - Political Will Strengthens Globally
Bradykinin
Nail_disease

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology - Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene
